Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
申请人:——
公开号:US20030069299A1
公开(公告)日:2003-04-10
Indolinones of general formula I
1
which are inhibitors of cell proliferation, particularly of tumour cells, and inhibitors of protein kinases. The following compounds are exemplary:
(Z)-3-{1-[4-(N-(2-aminoethyl)-N-methylsulphonyl-amino)-phenylamino]-1-phenyl-methylidene}-5-phenylsulphonylamino-2-indolinone,
(Z)-3-{1 -[4-(N-(2-dimethylaminoethyl)-N-phenylsulphonyl-amino)-phenylamino]-1-phenyl-methylidene}-5-phenylsulphonylamino-2-indolinone, and
(Z)-3-{1-[4-(4-methylpiperazinomethyl)-phenylamino]-1-phenyl-methylidene}-5-phenylsulphonylamino-2-indolinone.
[EN] MINERALOCORTICOID RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES D'UN RÉCEPTEUR DES MINÉRALOCORTICOÏDES
申请人:MERCK SHARP & DOHME
公开号:WO2013055607A1
公开(公告)日:2013-04-18
The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that are aldosterone receptor antagonists which might be useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).
New substituted indolinones, preparation thereof and their use as pharmaceutical compositions
申请人:Boehringer Ingelheim Pharma KG
公开号:US20040044222A1
公开(公告)日:2004-03-04
Indolinones of general formula I
1
which are inhibitors of cell proliferation, particularly of tumour cells, and inhibitors of protein kinases.
通式为I1的吲哚酮类化合物是细胞增殖抑制剂,尤其是肿瘤细胞的抑制剂,同时也是蛋白激酶的抑制剂。
Mineralocorticoid receptor antagonists
申请人:Shen Hong
公开号:US09193717B2
公开(公告)日:2015-11-24
The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that are aldosterone receptor antagonists which might be useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).